Drug Profile
Research programme: anticancer DARPin therapeutics - Molecular Partners
Alternative Names: anti-CD3-DARPin®; mFAP x CD40; Multispecific-DARPins - Molecular Partners; PD1-VEGF-targeting DARPin®; Peptide MHC DARPin®; pMHC-DARPins; T-cell engagersLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Molecular Partners AG
- Class Antineoplastics; Protein-drug conjugates; Proteins
- Mechanism of Action Apoptosis stimulants; CD3 antigen stimulants; ERBB 2 receptor antagonists; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cancer in Switzerland
- 10 Apr 2021 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 17 Sep 2019 Preclinical development is ongoing in Switzerland (Molecular Partners website, September 2019)